Skip to main content
Premium Trial:

Request an Annual Quote

Sticking Up for Avastin

Premium

FDA has granted Roche a public hearing to defend the effectiveness of Avastin in breast cancer, reports the Associated Press. Several months ago, the regulatory agency said the drug was "ineffective" in breast cancer — it's currently approved to treat colon, lung, kidney, and brain cancer — and in December, FDA began the process to revoke the drug's approval, AP adds. Roche's hearing is scheduled for June 28. The company's decision to challenge the ruling is "rare," AP says, and the meeting in June will be "the first of its kind."

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.